Drug
Izalontamab brengitecan clinical trials
Also written BL-B01D1 and BMS-986507.
Keep track of what changes. Save the izalontamab brengitecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
58 studies that test it; most in 2026 (16)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 11 |
| 2024 | 14 |
| 2025 | 13 |
| 2026 | 16 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 55 · Other 3
Sichuan Baili Pharmaceutical Co., Ltd. (49) · Bristol-Myers Squibb (5) · Fudan University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · SystImmune Inc. (1) · Sichuan University (1)
Often tested with
Tested in the same studies.
Immune Checkpoint Inhibitors (7) · Danvilostomig (7) · Osimertinib (3) · Docetaxel (3) · Gemcitabine (3) · Capecitabine (3) · Eribulin (2) · Vinorelbine (2)
Studies
Open first, then newest update. How each study uses izalontamab brengitecan is read from its arms, and is right about nine times in ten.
Testing it · 58
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingPhase 2/3Bristol-Myers SquibbNCT07100080Written as Iza-bren
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790Written as Iza-bren
- A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07729956Written as BL-B01D1
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingPhase 1SystImmune Inc.NCT05983432Written as BL-B01D1
- A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07827261Written as BL-B01D1
- A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)RecruitingPhase 2Bristol-Myers SquibbNCT06855771Written as Izalontamab Brengitecan
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Izalontamab brengitecan (iza-bren / BL-B01D1)
- A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07797881Written as BL-B01D1
- A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)Not yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07783321Written as BL-B01D1
- A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07640789Written as BL-B01D1
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05194982Written as BL-B01D1
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05262491Written as BL-B01D1
- A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05470348Written as BL-B01D1
- A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System TumorsRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05785039Written as BL-B01D1
- A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05924841Written as BL-B01D1
- A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)Not yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739199Written as BL-B01D1
- A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)Not yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739186Written as BL-B01D1
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingPhase 2/3Bristol-Myers SquibbNCT06926868Written as Iza-bren
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07642024Written as BL-B01D1
- Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyRecruitingPhase 2/3Bristol-Myers SquibbNCT07106762Written as Iza-bren
See all 58 studies that test izalontamab brengitecan →
Given in every arm · 2 — izalontamab brengitecan is usual care beside what is tested
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT06618287Written as BMS-986507
- Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT07382726Written as Iza-bren
Codes
What other systems call izalontamab brengitecan · ClinicalTrials.gg INT018114
- UNII (FDA) UC2FX6YY3PIZALONTAMAB BRENGITECANOne source FDA
- NCI Thesaurus C203048Izalontamab BrengitecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UC2FX6YY3P | IZALONTAMAB BRENGITECAN | One source FDA |
| NCI Thesaurus | C203048 | Izalontamab Brengitecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.